CV Sciences: From CBD to Health & Wellness — Regulatory Delay Buys Time for a Pivot
The $5.6M hemp supplier is cutting costs, launching a non-cannabinoid brand, and banking on a one-month regulatory reprieve.
CVSI · Earnings Call · 2026-08-13
A Micro-Cap in the Squeeze
CV Sciences (CVSI) is a $5.6 million micro-cap that has lost 99.6% of its value since its 2014 peak, and in the last 90 trading days it dropped another 44.9%. The once-highflying hemp CBD brand is now a lean operator fighting for survival. Q2 2026 revenue was $3 million, down 17% year-over-year and 7% sequentially, with unit sales down 15%. Management describes this as a constrained revenue environment. The company's total revenue is now only a fifth of its 2019 peak. Yet gross margin held at 48.6%, and SG&A fell 10% to $1.7 million. CFO Joerg Grasser credited "lower legal and professional fees, reduced marketing spend and broader administrative efficiencies" (“lower legal and professional fees, reduced marketing spend and broader administrative efficiencies” — Joerg Grasser, Chief Financial Officer · 2026-08-13). These cuts are structural, he said, meant to align the cost base with current revenue and provide operating leverage when the market recovers. Adjusted EBITDA loss was just $0.1 million, essentially flat sequentially, and the company still claims the “We maintained our position as the #1 selling hemp extract brand in the natural product retail sales channel” — Joseph Dowling, Chief Executive Officer · 2026-08-13.
The PlusHLTH Pivot
The most ambitious strategic move is the launch of PlusHLTH.com, a direct-to-consumer destination for the PlusHLTH product line, which includes protein powders like Empower (20g protein, 5g creatine), gummies, and supplements for cognitive health, metabolism, and cardiovascular wellness. CEO Joseph Dowling said: “The launch of PlusHLTH.com represents an important milestone for our long-term strategy to expand beyond cannabinoids and establish +PlusHLTH as a leading brand focused on healthy aging, performance and everyday health.” — Joseph Dowling, Chief Executive Officer · 2026-08-13 The company is also leaning on its European subsidiary, Cultured Foods, for manufacturing and as a springboard into international markets. These non-cannabinoid products are designed to offset regulatory pressure on the core CBD business. Management expects multiple product launches through the rest of 2026, leveraging existing infrastructure and the new direct-to-consumer platform.
Regulatory Tailwind and the Long Game
The most consequential news came from Washington. On August 8, the U.S. Senate passed a continuing resolution (H.R. 6500) that would delay implementation of the Appropriations Act provisions on hemp-derived products by one month, from November 12 to December 11, 2026. Dowling expressed cautious optimism, describing the bipartisan 61-32 vote as a reason for hope. He detailed the provision:
The company remains prepared to modify its product offering if the act stands, but it is also monitoring potential rescheduling of cannabis and other modernization efforts.The 2027 continuing resolution includes language that would delay most of the implementation of the regulatory changes applicable to hemp-derived cannabinoid products described in the November 2025 Appropriations Act. Specifically, the effective date of those provisions would be delayed from November 12, 2026, to December 11, 2026, if the bill is enacted with its current language.
Cash Flow and the Road to Breakeven
CV Sciences generated positive operating cash flow of approximately $20,000 in Q2, following a positive Q1 — a meaningful milestone for a company that has burned cash for years. Management is explicitly targeting cash flow breakeven. Dowling stated: “We are approaching cash flow breakeven even in a constrained revenue and rising environment.” — Joseph Dowling, Chief Executive Officer · 2026-08-13 The company's gross margin of 48.6% is a bright spot, down from 50.9% a year ago but stable sequentially. The direct-to-consumer channel accounted for 46.2% of revenue, and while it slipped slightly, Grasser noted improving digital performance metrics. Liquidity remains tight: just $0.3 million in cash and $4.0 million in inventory, with liabilities-to-assets at 77.7%. During the quarter, $0.7 million of convertible note principal was converted.
Analyst Silence
Notably, the Q&A session was again empty. In the prior quarter (May 2026), the pattern was the same, with the operator saying: “There are no questions from the analyst community at this time.” — Operator, Operator · 2025-05-14 And in March 2026, the CEO closed with a hopeful, “We are excited about the future and look forward to speaking again soon.” — Joseph Dowling, Chief Executive Officer · 2026-05-14 This micro-cap is flying under the radar, but its pivot, its cash discipline, and the regulatory reprieve could give it a narrow path to stability.